Catechol-O-methyl transferase: pharmacological aspects and physiological role.

Suppr

超能文献

作者信息

Guldberg H C, Marsden C A

出版信息

Pharmacol Rev. 1975 Jun;27(2):135-206.

PMID:1103160

Abstract

摘要

相似文献

Catechol-O-methyl transferase: pharmacological aspects and physiological role.

Pharmacol Rev. 1975 Jun;27(2):135-206.

Sensitization to the generalized Shwartzman reaction by catechol-O-methyltransferase inhibitors.

Am J Pathol. 1978 Aug;92(2):377-87.

Catechol metabolites of polychlorinated biphenyls inhibit the catechol-O-methyltransferase-mediated metabolism of catechol estrogens.

Toxicol Appl Pharmacol. 2000 Jan 15;162(2):115-23. doi: 10.1006/taap.1999.8823.

2-Hydroxyoestrogens. Chemistry, biogenesis, metabolism and physiological significance.

Adv Steroid Biochem Pharmacol. 1977;6:81-154.

Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases.

Chem Res Toxicol. 2007 Oct;20(10):1409-25. doi: 10.1021/tx700174w. Epub 2007 Sep 20.

The effect of catechol-O-methyl transferase inhibitors on behavior and dopamine metabolism.

Adv Biochem Psychopharmacol. 1974;12(0):339-51.

Catecholamine metabolism: basic aspects and clinical significance.

Pharmacol Rev. 1985 Dec;37(4):333-64.

Catechol-O-methyltransferase and its role in catecholamine metabolism.

Adv Neurol. 1990;53:489-95.

Inhibition of catechol-O-methyl transferase by pyrogallol in the rat.

Biochem Pharmacol. 1961 Apr;6:47-50. doi: 10.1016/0006-2952(61)90067-3.

Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation.

Mol Pharmacol. 2006 Jul;70(1):143-53. doi: 10.1124/mol.106.023119. Epub 2006 Apr 17.

引用本文的文献

COMT inhibition with entacapone for patients with Parkinson's disease and motor complications: the novelty of continuous infusion.

J Neural Transm (Vienna). 2025 Sep 2. doi: 10.1007/s00702-025-03006-x.

Pain Intensity in Patients with Opioid Use Disorder on Extended-Release Naltrexone or Opioid Agonists; The Role of COMT rs4680 and OPRM1 rs1799971: An Exploratory Study.

J Pain Res. 2025 Feb 21;18:827-836. doi: 10.2147/JPR.S500984. eCollection 2025.

Therapeutic Role of Scutellarein in Neurological Disorders.

Curr Pharm Des. 2025;31(20):1583-1592. doi: 10.2174/0113816128336901241125092132.

Recent Progress in Synthetic and Natural Catechol--methyltransferase Inhibitors for Neurological Disorders.

ACS Omega. 2024 Oct 23;9(44):44005-44018. doi: 10.1021/acsomega.4c06190. eCollection 2024 Nov 5.

Cellular and Mitochondrial Toxicity of Tolcapone, Entacapone, and New Nitrocatechol Derivatives.

ACS Pharmacol Transl Sci. 2024 Apr 30;7(5):1637-1649. doi: 10.1021/acsptsci.4c00124. eCollection 2024 May 10.

The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications.

CNS Drugs. 2024 May;38(5):315-331. doi: 10.1007/s40263-024-01073-4. Epub 2024 Apr 3.

The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation.

BMC Pharmacol Toxicol. 2022 May 31;23(1):33. doi: 10.1186/s40360-022-00574-6.

Interspecies comparison in the COMT-mediated methylation of 3-BTD.

RSC Adv. 2018 May 1;8(29):16278-16284. doi: 10.1039/c8ra01938j. eCollection 2018 Apr 27.

Discovery and characterization of naturally occurring potent inhibitors of catechol--methyltransferase from herbal medicines.

RSC Adv. 2021 Mar 11;11(17):10385-10392. doi: 10.1039/d0ra10425f. eCollection 2021 Mar 5.

Discovery of Small Molecules as Membrane-Bound Catechol--methyltransferase Inhibitors with Interest in Parkinson's Disease: Pharmacophore Modeling, Molecular Docking and In Vitro Experimental Validation Studies.

Pharmaceuticals (Basel). 2021 Dec 31;15(1):51. doi: 10.3390/ph15010051.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验